Abstracts Archive - Page 1415 of 2607 - ACR Meeting Abstracts

Abstract Number: 416 • 2017 ACR/ARHP Annual Meeting
The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX
LA Trouw¹, SE Connolly², A Johnsen², J Ye², MA Maldonado², REM Toes¹ and TWJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Maturation of autoantibody responses has been suggested to be a proxy for disease maturation. Autoantibody responses against post-translationally modified antigens are present in autoimmune…
Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Yoshiya Tanaka¹, Hideto Kameda², Kazuyoshi Saito³, Yuko Kaneko⁴, Eiichi Tanaka⁵, Shinsuke Yasuda⁶, Naoto Tamura⁷, Keishi Fujio⁸, Takao Fujii⁹, Toshihisa Kojima¹⁰, Tatsuhiko Anzai¹¹, Chikuma Hamada¹², Yoshihisa Fujino¹³, Shinya Matsuda¹³ and Hitoshi Kohsaka¹⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ³Tobata General Hospital, Fukuoka, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁷Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, ¹⁰Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ¹¹Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, ¹²Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, ¹³Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
Abstract Number: 418 • 2017 ACR/ARHP Annual Meeting
Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline
Désirée van der Heijde¹, Patrick Durez², Georg Schett³, Esperanza Naredo⁴, Mikkel Østergaard⁵, Gabriella Meszaros⁶, Pedro Lopez-Romero⁷, Francesco de Leonardis⁶ and Roy Fleischmann⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²UCL-Saint Luc, Bruxelles, Belgium, ³Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ⁴Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain, ⁵Glostrup Hospital, Rigshospitalet, Glostrup, Denmark, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Europe Research Center, Eli Lilly and Company, Madrid, Spain, ⁸University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Baricitinib (BARI), an oral inhibitor of Janus kinase (JAK)1 and JAK2, is being developed for the treatment of RA. RA-BEGIN (NCT01711359) was a phase…
Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting
Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience
Omar Valenzuela¹, María Paz Poblete², Claudia Mardones², Sebastián Ibáñez¹, Katherine Mogollones², Francisco Silva¹ and María José Villar², ¹Rheumatology department, Hospital Padre Hurtado, Santiago, Chile, ²Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…
Abstract Number: 420 • 2017 ACR/ARHP Annual Meeting
Machine Learning in Rheumatology: Development and Validation of a Predictive Model for Rheumatoid Arthritis Mortality Using Random Survival Forests
Luis Rodriguez-Rodriguez¹, José M Lezcano-Valverde², Fernando Salazar³, Leticia León², Esther Toledano⁴, Juan A Jover Jover⁵, Eduardo Soudah³, Benjamín Fernández-Gutiérrez⁵, Isidoro Gonzalez-Alvaro⁶ and Lydia A Alcazar¹, ¹Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ²Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ³International Centre for Numerical Methods in Engineering (CIMNE), Madrid, Spain, ⁴Rheumatology, Hospital Clínical San Carlos, Madrid, Spain, ⁵Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality. Traditional survival techniques used to identify mortality risk factors, such as the Cox proportional hazards model…
Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Nathan den Broeder¹, Lieke Tweehuysen¹, Noortje van Herwaarden¹, Thomas Vogl², F.H.J. van den Hoogen¹, Rogier Thurlings³ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²University of Muenster, Muenster, Germany, ³Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…
Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Lieke Tweehuysen¹, Nathan den Broeder¹, Leo .A.B. Joosten², Thomas Vogl³, F.H.J. van den Hoogen⁴, Rogier Thurlings⁵ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ³University of Muenster, Muenster, Germany, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…
Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Tor Olofsson¹, Johan K Wallman², Maria EC Schelin³, Anna Jöud⁴ and Jon Lampa⁵, ¹Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences Lund, Oncology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Laboratory Medicine Lund, Division of Occupational and Environmental Medicine, Lund, Sweden, Lund, Sweden, ⁵Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…
Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Jeffrey Kaine¹, John Tesser², Ryan DeMasi³, Liza Takiya³, Lisy Wang⁴, Mark Snyder³, Haiyun Fan⁴ and Jürgen Wollenhaupt⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…
Abstract Number: 425 • 2017 ACR/ARHP Annual Meeting
Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry
Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the prevalence and efficacy of biologic DMARD (bDMARD) monotherapy in real life treatment of rheumatoid arthritis (RA). Methods: RA patients registered in…
Abstract Number: 426 • 2017 ACR/ARHP Annual Meeting
Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
Chi Chiu Mok¹, Lai Shan Fong¹, Ling Yin Ho² and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the correlation between levels of the anti-TNF biologics and clinical efficacy in patients with inflammatory arthritis Methods: Adult patients who fulfilled the…
Abstract Number: 427 • 2017 ACR/ARHP Annual Meeting
Do We Treat Men and Women Differently, and Is This a Good Thing?
Sytske Anne Bergstra¹, Cornelia F Allaart¹, Sofia Ramiro², Arvind Chopra³, Candida A. Silva⁴, Nimmisha Govind⁵ and Robert B.M. Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, India, Pune, India, ⁴Instituto Português de Reumatologia, Lisbon, Portugal, Lisbon, Portugal, ⁵Department of Rheumatology, University of the Witwatersrand, Johannesburg, South-Africa, Johannesburg, South Africa, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁷Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Men seem to respond better to antirheumatic treatment than women with RA. In daily practice, expectations towards responsiveness may influence rheumatologists when making treatment…
Abstract Number: 428 • 2017 ACR/ARHP Annual Meeting
Impact of Smoking Cessstion Advise in Patients with Rheumatoid Arthritis to Help Quit Smoking
Shama Khan¹, Ahmad Butt¹, Emmett Brennan², Ausaf Mohammad¹ and Killian O Rourke³, ¹Rheumatology, Midlands Regional Hospital, Tullamore, Ireland, ²Tullamore, Midlands Regional Hospital, Tullamore, Ireland, ³Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland
Background/Purpose: Smoking is associated with an increased risk of comorbidities in rheumatoid arthritis (RA) and may reduce the efficacy of anti-rheumatic therapies. Smoking cessation is…
Abstract Number: 429 • 2017 ACR/ARHP Annual Meeting
Repair of Joint Damage Is Rare in Newly Diagnosed Rheumatoid Arthritis Patients and Appears Not to Relate to Previous Suppression of Inflammation
Joy A. van der Pol¹, Gulsah Akdemir¹, Marianne van den Broek¹, Linda Dirven¹, Pit J.S.M. Kerstens², Willem F. Lems³, Iris M. Markusse¹, Cornelia F Allaart¹ and Tom W.J. Huizinga¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Reade, Amsterdam, Netherlands, ³Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Joint damage in RA is thought to be irreparable. We hypothesized that in patients in whom inflammation is persistently well suppressed, repair may be…
Abstract Number: 430 • 2017 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Remission Strategy for Rheumatoid Arthritis in Australian Public and Private Rheumatology Clinics – Identification of Clinician and Patient Barriers
Helen Benham¹, Hedva Chiu², Joanne Tesiram³, Peter Landsberg⁴, Andrew A. Harrison⁵, Peter Nash⁶, Ranjeny Thomas⁷ and Mieke van Driel⁸, ¹The University of Queensland Faculty of Medicine, Brisbane, Australia, ²The University of Queensland Faculty of Medicine, Woolloongabba, Australia, ³Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Woolloongabba, Australia, ⁵Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁶University of Queensland, Brisbane, Australia, ⁷Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, ⁸Primary Care Clinical Unit, The University of Queensland Faculty of Medicine, Herston, Australia
Background/Purpose: Treat-to-target in rheumatoid arthritis (RA-T2T) improves outcomes for people living with RA. Implementing T2T in routine clinical practice however presents many challenges and an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].